SGLT-2 inhibitors for type 2 diabetes
=====================================


In the January 2021 issue, in Tsushima Y, Lansang MC, Makin V. The role of SGLT-2 inhibitors in managing type 2 diabetes. Cleve Clin J Med 2021; 88(1):47–58. doi:10.3949/ccjm.88a.20088, a sentence on page [52](http://www.ccjm.org/lookup/doi/10.3949/ccjm.88a.20088) contained an error: “However, in January 2020, the 100-mg once-daily dose was approved for use in patients with eGFR 30 to 44 mL/min/1.73 m2 with urinary albumin excretion less than 300 mg/day.” The 100-mg once-daily dose was approved for use in patients with eGFR 30 to 44 mL/min/1.73 m2 with urinary albumin excretion **more than** 300 mg/day. This has been corrected online.

*   Copyright © 2021 The Cleveland Clinic Foundation. All Rights Reserved.